Dr. Dave Rabin MD, PhD, a psychiatrist and neuroscientist trained in Ketamine and MDMA-assisted therapy, brings you the newest developments from the world of psychedelic science and technology. From researchers and investors to physicians and shamans to nonprofit pioneers and policy-makers — each week, Dr. Dave brings you the latest news and answers your questions to share perspectives from the front lines of this exciting movement.
All content for The Psychedelic Report is the property of Dr. Dave Rabin and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dr. Dave Rabin MD, PhD, a psychiatrist and neuroscientist trained in Ketamine and MDMA-assisted therapy, brings you the newest developments from the world of psychedelic science and technology. From researchers and investors to physicians and shamans to nonprofit pioneers and policy-makers — each week, Dr. Dave brings you the latest news and answers your questions to share perspectives from the front lines of this exciting movement.
In this episode, Dr. Dave Rabin discusses the impact of the FDA's decision, the potential delays in accessing this crucial treatment, and the unethical behavior of certain organizations influencing the FDA. Dr. Rabin is joined by Jon Lubecky, a retired army sergeant and Veteran who took part in MAPS MDMA therapy trials, as he discusses the implications of this rejection and emphasizes the need for ongoing advocacy and hope for eventual approval. The episode also addresses the unethical behavior of Symposia, an organization accused of falsifying information to the FDA to obstruct MDMA therapy approval. Additionally, former Symposia member David Nichols reveals serious ethical violations within the organization, raising questions about their motives and funding. Through these discussions, the episode highlights the critical need for transparency, ethical practices, and continued efforts to ensure access to psychedelic treatments for those in need. Rachel Nuwer’s Scientific American Article: https://www.scientificamerican.com/article/fdas-rejection-of-mdma-psychotherapy-for-trauma-draws-criticism-from/ Jon Lubecky’s Conversation with David Nickles on Breaking Points: https://www.youtube.com/watch?v=lttFB0c0cAo
Food and Drug Administration5630 Fishers LaneRm. 1061Rockville, MD 20852Docket No. FDA-2024-N-193
The Psychedelic Report
Dr. Dave Rabin MD, PhD, a psychiatrist and neuroscientist trained in Ketamine and MDMA-assisted therapy, brings you the newest developments from the world of psychedelic science and technology. From researchers and investors to physicians and shamans to nonprofit pioneers and policy-makers — each week, Dr. Dave brings you the latest news and answers your questions to share perspectives from the front lines of this exciting movement.
